Ranbaxy Laboratories Ltd. (500359.BY) Tuesday said it has launched an authorized generic version of Pfizer Inc.'s (PFE) Caduet blood-pressure pill in the U.S. as part of an agreement with the U.S. drug maker.

Caduet is a fixed-dose combination of atorvastatin-amlodipine besylate and is indicated for patients suffering from both high blood pressure and high levels of cholesterol, the Indian generic drug maker said in a statement.

For the year ended Sept. 30, Caduet sales were about $339 million.

Ranbaxy, a unit of Japan's Daiichi Sankyo Co. (4568.TO), had last week launched a generic version of Pfizer's blockbuster cholesterol-lowering drug Lipitor in the U.S. Simultaneously, Watson Pharmaceuticals Inc. (WPI) had launched an authorized generic version of Lipitor.

-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com

Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Daiichi Sankyo (PK) Charts.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Daiichi Sankyo (PK) Charts.